New obesity combo drug tested in small safety study

NCT ID NCT06972992

Completed Disease control Sponsor: Ascletis Pharma (China) Co., Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tested a new drug called ASC47, given as a shot under the skin, combined with the weight-loss drug semaglutide in 28 adults with obesity. The study was double-blind and placebo-controlled, meaning some participants got a dummy shot. The main goal was to check safety and side effects, but researchers also measured weight changes over 10 weeks. Because this is an early-stage study, the focus is on whether the combination is safe enough to test further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASC47 injection plus semaglutide
What this could lead to: If it works, this could lead to a new combination treatment for obesity that helps people lose more weight than semaglutide alone.
What could go wrong: This is a very early Phase 1 trial with only 28 people, so results may not apply to everyone. The main goal is safety, not weight loss, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC WEIGHT MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC WEIGHT MANAGEMENT

Contacts and locations

Locations

Ascletis Clinical Site

San Antonio, Texas, 78209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.